Hong Kong Daily Briefing

Hong Kong-listed biotech Akeso Inc. (9926.HK) announced that its B7-H3-targeting antibody-drug conjugate (ADC) AK157D1 has received Phase I clinical trial clearance from China's National Medical Products Administration's Center for Drug Evaluation. This is Akeso's third differentiated ADC entering the clinic, adding pipeline depth to the company's growing antibody platform beyond its commercial-stage PD-1 assets. The Hong Kong biotech sector has been a key beneficiary of the HKEX's Chapter 18A listing framework, which allowed pre-revenue biotech companies to list on HKEX — and Akeso is among the better-performing cohort. For HK biotech investors tracking the ADC wave: a B7-H3 target in solid tumors is an active competitive landscape (competing with firms like MacroGenics and Iconic Therapeutics globally), so differentiation data from the Phase I readout will be the key re-rating moment.

Tesla and eight other Chinese automakers announced a combined recall of approximately 4.3 million vehicles in China over door emergency-opening safety concerns — the largest automotive recall in Chinese market history, Manila Times reported. The move comes as Chinese regulators push to ban retractable car door handles, a technology Tesla pioneered and domestic EV makers copied. Despite the negative headline, the EV/Mobility sector still closed the session up 1.60% on the HK-proxy data, suggesting markets are treating the recall as a one-time compliance cost rather than a demand signal. For HK investors in Xpeng, Li Auto, and NIO secondary listings, the read is nuanced: Chinese regulators are tightening product safety standards, which raises compliance costs for all makers but most acutely for foreign brands like Tesla that have already been in the crosshairs of China's market-access regulators.

A consortium of Amwins Group, Dragoneer Investment, and KKR has finalized a deal to take ASX-listed insurance broking group Steadfast private in a A$7.7 billion transaction, FinanceAsia Hong Kong reported. While the deal is Australian, its significance for HK market participants is the PE deployment signal: KKR's Asia-Pacific capital continues to find premium-priced buyout targets in Australian financial services, a sector KKR has been active in regionally. For HK-focused Asia PE investors, Australia's insurance sector is a recurring target given stable regulatory environment, high intermediated revenue, and institutional consolidation tailwinds. The HKEX-listed PE names — particularly those with Australia exposure — are worth monitoring for secondary flow from this deal's capital deployment signal.